$BBNX Stock Notification: Beta Bionics has been Sued for Securities Fraud after Medical Device Safety Issues Disclosed – Investors are Alerted to Contact BFA Law by November 3

A securities class action (Holtzman v. Beta Bionics, No. 26-cv-9999) is pending against Beta Bionics in the Central District of California, and Bleichmar Fonti & Auld LLP is soliciting investors to seek lead-plaintiff status before a November 3, 2026 deadline. The complaint alleges the company misled investors about iLet safety, citing a June 2025 FDA Form 483 detailing more than 18,000 unreported user complaints including life-threatening hypoglycemia, and a subsequent FDA warning letter released February 24, 2026.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.